CoChat
Sign Up
Cited by 106

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Retroviral Integrations in Gene Therapy Trials

Biasco, Luca, Baricordi, Cristina, Aiuti, Alessandro·2012·Molecular Therapy
DOI 10.1038/mt.2011.289PMC PMC3321603
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2011.289

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 9 references

Research works printed but not linked: 81

  1. Naldini, 2011, Ex vivo gene transfer and correction for cell-based therapies, Nat Rev Genet, 12, 301, 10.1038/nrg2985 · DOI
  2. Rossi, 2007, Genetic therapies against HIV, Nat Biotechnol, 25, 1444, 10.1038/nbt1367 · DOI
  3. Deeks, 2002, A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy, Mol Ther, 5, 788, 10.1006/mthe.2002.0611 · DOI
  4. Mavilio, 2006, Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells, Nat Med, 12, 1397, 10.1038/nm1504 · DOI
  5. Ciceri, 2009, Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study, Lancet Oncol, 10, 489, 10.1016/S1470-2045(09)70074-9 · DOI
  6. Boztug, 2010, Stem-cell gene therapy for the Wiskott-Aldrich syndrome, N Engl J Med, 363, 1918, 10.1056/NEJMoa1003548 · DOI · Paper page
  7. Hacein-Bey-Abina, 2010, Efficacy of gene therapy for X-linked severe combined immunodeficiency, N Engl J Med, 363, 355, 10.1056/NEJMoa1000164 · DOI
  8. Cavazzana-Calvo, 2000, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, 669, 10.1126/science.288.5466.669 · DOI
  9. Aiuti, 2002, Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement, Nat Med, 8, 423, 10.1038/nm0502-423 · DOI
  10. Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency, N Engl J Med, 360, 447, 10.1056/NEJMoa0805817 · DOI
  11. Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
  12. Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1, Nat Med, 12, 401, 10.1038/nm1393 · DOI
  13. Stein, 2010, Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, Nat Med, 16, 198, 10.1038/nm.2088 · DOI
  14. Deichmann, 2007, Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy, J Clin Invest, 117, 2225, 10.1172/JCI31659 · DOI
  15. Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J Clin Invest, 118, 3143, 10.1172/JCI35798 · DOI · Paper page
  16. Aiuti, 2007, Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy, J Clin Invest, 117, 2233, 10.1172/JCI31666 · DOI
  17. Biasco, 2011, Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell, EMBO Mol Med, 3, 89, 10.1002/emmm.201000108 · DOI
  18. Schwarzwaelder, 2007, Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo, J Clin Invest, 117, 2241, 10.1172/JCI31661 · DOI
  19. Schmidt, 2009, Detection of retroviral integration sites by linear amplification-mediated PCR and tracking of individual integration clones in different samples, Methods Mol Biol, 506, 363, 10.1007/978-1-59745-409-4_24 · DOI
  20. Fischer, 2008, Gene therapy of inherited diseases, Lancet, 371, 2044, 10.1016/S0140-6736(08)60874-0 · DOI
  21. Gaspar, 2011, Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency, Sci Transl Med, 3, 97ra79, 10.1126/scitranslmed.3002715 · DOI
  22. Rabbitts, 1998, LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes, Genes Dev, 12, 2651, 10.1101/gad.12.17.2651 · DOI
  23. Bester, 2006, Fragile sites are preferential targets for integrations of MLV vectors in gene therapy, Gene Ther, 13, 1057, 10.1038/sj.gt.3302752 · DOI
  24. Davé, 2004, Gene therapy insertional mutagenesis insights, Science, 303, 333, 10.1126/science.1091667 · DOI
  25. Davé, 2009, Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy, PLoS Genet, 5, e1000491, 10.1371/journal.pgen.1000491 · DOI
  26. Woods, 2006, Gene therapy: therapeutic gene causing lymphoma, Nature, 440, 1123, 10.1038/4401123a · DOI
  27. Pike-Overzet, 2006, Gene therapy: is IL2RG oncogenic in T-cell development?, Nature, 443, E5, 10.1038/nature05218 · DOI
  28. Pike-Overzet, 2007, New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy, Mol Ther, 15, 1910, 10.1038/sj.mt.6300297 · DOI
  29. Ginn, 2010, Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression, Mol Ther, 18, 965, 10.1038/mt.2010.50 · DOI
  30. Avedillo Diez, 2011, Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy, Mol Pharm, 8, 1525, 10.1021/mp200132u · DOI
  31. Trobridge, 2011, Genotoxicity of retroviral hematopoietic stem cell gene therapy, Expert Opin Biol Ther, 11, 581, 10.1517/14712598.2011.562496 · DOI
  32. Ott, 2002, Mobilization and transduction of CD34(+) peripheral blood stem cells in patients with X-linked chronic granulomatous disease, J Hematother Stem Cell Res, 11, 683, 10.1089/15258160260194839 · DOI
  33. Grez, 2011, Gene therapy of chronic granulomatous disease: the engraftment dilemma, Mol Ther, 19, 28, 10.1038/mt.2010.232 · DOI
  34. Seger, 2010, Chronic granulomatous disease: recent advances in pathophysiology and treatment, Neth J Med, 68, 334
  35. Kang, 2010, Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils, Blood, 115, 783, 10.1182/blood-2009-05-222760 · DOI
  36. Calmels, 2005, Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells, Blood, 106, 2530, 10.1182/blood-2005-03-1115 · DOI
  37. Mitchell, 2004, Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences, PLoS Biol, 2, E234, 10.1371/journal.pbio.0020234 · DOI
  38. Wu, 2003, Transcription start regions in the human genome are favored targets for MLV integration, Science, 300, 1749, 10.1126/science.1083413 · DOI · Paper page
  39. Ikeda, 2011, 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice, Blood, 117, 5860, 10.1182/blood-2011-02-334425 · DOI
  40. Gaspar, 2011, Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction, Sci Transl Med, 3, 97ra80, 10.1126/scitranslmed.3002716 · DOI
  41. Ferrua, 2010, Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency, Curr Opin Allergy Clin Immunol, 10, 551, 10.1097/ACI.0b013e32833fea85 · DOI
  42. Shin, 2004, High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas, Cancer Res, 64, 4419, 10.1158/0008-5472.CAN-03-3885 · DOI
  43. Mikkers, 2003, Retroviral insertional mutagenesis: tagging cancer pathways, Adv Cancer Res, 88, 53
  44. Kim, 2003, Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas, J Virol, 77, 2056, 10.1128/JVI.77.3.2056-2062.2003 · DOI
  45. Lund, 2002, Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice, Nat Genet, 32, 160, 10.1038/ng956 · DOI
  46. Cattoglio, 2007, Hot spots of retroviral integration in human CD34+ hematopoietic cells, Blood, 110, 1770, 10.1182/blood-2007-01-068759 · DOI
  47. Biffi, 2011, Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection, Blood, 117, 5332, 10.1182/blood-2010-09-306761 · DOI
  48. Deichmann, 2011, Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy, Mol Ther, 19, 2031, 10.1038/mt.2011.178 · DOI
  49. Kustikova, 2005, Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking, Science, 308, 1171, 10.1126/science.1105063 · DOI
  50. Kustikova, 2007, Retroviral vector insertion sites associated with dominant hematopoietic clones mark “stemness” pathways, Blood, 109, 1897, 10.1182/blood-2006-08-044156 · DOI
  51. Shimizu, 2002, EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation, Biochem Biophys Res Commun, 292, 609, 10.1006/bbrc.2002.6693 · DOI
  52. Cassani, 2009, Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy, Blood, 114, 3546, 10.1182/blood-2009-02-202085 · DOI
  53. Recchia, 2006, Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells, Proc Natl Acad Sci USA, 103, 1457, 10.1073/pnas.0507496103 · DOI
  54. Baum, 2011, Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials, EMBO Mol Med, 3, 75, 10.1002/emmm.201000110 · DOI
  55. Gabriel, 2009, Comprehensive genomic access to vector integration in clinical gene therapy, Nat Med, 15, 1431, 10.1038/nm.2057 · DOI
  56. Kustikova, 2009, Longitudinal analysis of insertional mutants in a murine model of hematopoietic stem cell transplantation (Meeting Abstract), Hum Gene Ther, 20, 1507
  57. Paruzynski, 2010, Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing, Nat Protoc, 5, 1379, 10.1038/nprot.2010.87 · DOI
  58. Brady, 2011, A method to sequence and quantify DNA integration for monitoring outcome in gene therapy, Nucleic Acids Res, 39, e72, 10.1093/nar/gkr140 · DOI
  59. Gillet, 2011, The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones, Blood, 117, 3113, 10.1182/blood-2010-10-312926 · DOI
  60. Kircher, 2010, High-throughput DNA sequencing–concepts and limitations, Bioessays, 32, 524, 10.1002/bies.200900181 · DOI
  61. Wu, 2006, Redefining the common insertion site, Virology, 344, 292, 10.1016/j.virol.2005.08.047 · DOI
  62. de Ridder, 2006, Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens, PLoS Comput Biol, 2, e166, 10.1371/journal.pcbi.0020166 · DOI
  63. Cattoglio, 2010, High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors, Blood, 116, 5507, 10.1182/blood-2010-05-283523 · DOI
  64. Presson, 2011, Methodology and software to detect viral integration site hot-spots, BMC Bioinformatics, 12, 367, 10.1186/1471-2105-12-367 · DOI
  65. Ciuffi, 2005, A role for LEDGF/p75 in targeting HIV DNA integration, Nat Med, 11, 1287, 10.1038/nm1329 · DOI · Paper page
  66. Lewinski, 2005, Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription, J Virol, 79, 6610, 10.1128/JVI.79.11.6610-6619.2005 · DOI
  67. Brady, 2009, HIV integration site distributions in resting and activated CD4+ T cells infected in culture, AIDS, 23, 1461, 10.1097/QAD.0b013e32832caf28 · DOI
  68. Ocwieja, 2011, HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2, PLoS Pathog, 7, e1001313, 10.1371/journal.ppat.1001313 · DOI · Paper page
  69. Cherepanov, 2003, HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells, J Biol Chem, 278, 372, 10.1074/jbc.M209278200 · DOI · Paper page
  70. Llano, 2004, LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes, J Virol, 78, 9524, 10.1128/JVI.78.17.9524-9537.2004 · DOI · Paper page
  71. Urnov, 2010, Genome editing with engineered zinc finger nucleases, Nat Rev Genet, 11, 636, 10.1038/nrg2842 · DOI · Paper page
  72. Urnov, 2005, Highly efficient endogenous human gene correction using designed zinc-finger nucleases, Nature, 435, 646, 10.1038/nature03556 · DOI
  73. Gabriel, 2011, An unbiased genome-wide analysis of zinc-finger nuclease specificity, Nat Biotechnol, 29, 816, 10.1038/nbt.1948 · DOI · Paper page
  74. Bell, 2008, The earliest thymic progenitors for T cells possess myeloid lineage potential, Nature, 452, 764, 10.1038/nature06840 · DOI · Paper page
  75. Doulatov, 2010, Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development, Nat Immunol, 11, 585, 10.1038/ni.1889 · DOI
  76. Adolfsson, 2005, Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment, Cell, 121, 295, 10.1016/j.cell.2005.02.013 · DOI
  77. Kawamoto, 2010, A revised scheme for developmental pathways of hematopoietic cells: the myeloid-based model, Int Immunol, 22, 65, 10.1093/intimm/dxp125 · DOI
  78. Wang, 2010, Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial, Blood, 115, 4356, 10.1182/blood-2009-12-257352 · DOI
  79. Dykstra, 2007, Long-term propagation of distinct hematopoietic differentiation programs in vivo, Cell Stem Cell, 1, 218, 10.1016/j.stem.2007.05.015 · DOI
  80. Gerrits, 2010, Cellular barcoding tool for clonal analysis in the hematopoietic system, Blood, 115, 2610, 10.1182/blood-2009-06-229757 · DOI
  81. Lu, 2011, Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding, Nat Biotechnol, 29, 928, 10.1038/nbt.1977 · DOI

Cited by

Sorted by citations

Metadata

Authors
Biasco, L., Baricordi, C., & Aiuti, A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2012-04
Volume
20
Issue
4
Pages
709-716
ISSN
1525-0016
DOI
10.1038/mt.2011.289
PMC
PMC3321603
Cited by
106
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review